REPEATED PRENATAL EXPOSURE TO VALPROIC ACID RESULTS IN CEREBELLAR HYPOPLASIA AND ATAXIA

被引:46
|
作者
Main, Stacey L. [1 ]
Kulesza, Randy J. [1 ]
机构
[1] Lake Erie Coll Osteopath Med, Dept Anat, 1858 West Grandview Blvd, Erie, PA 16504 USA
关键词
autism; Purkinje cell; teratogen; enrichment; calbindin; BINDING PROTEINS PARVALBUMIN; SUPERIOR OLIVARY COMPLEX; ECTOPIC PURKINJE-CELLS; IN-UTERO EXPOSURE; BRAIN-STEM; RAT MODEL; ANTIEPILEPTIC DRUGS; ANIMAL-MODEL; ENVIRONMENTAL ENRICHMENT; DEVELOPMENTAL TOXICITY;
D O I
10.1016/j.neuroscience.2016.10.052
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Autism spectrum disorder (ASD) is a developmental brain disorder characterized by restricted and repetitive patterns of behavior, social and communication defects, and is commonly associated with difficulties with motor coordination. The etiology of ASD, while mostly idiopathic, has been linked to hereditary factors and teratogens, such as valproic acid (VPA). VPA is used clinically to treat epilepsy, mood disorders, and in the prevention of migraines. The use of VPA during pregnancy significantly increases the risk of ASD in the offspring. Neuropathological studies show decreased cerebellar function in patients with ASD, resulting in gait, balance and coordination impairments. Herein, we have exposed pregnant rats to a repeated oral dose of VPA on embryonic days 10 and 12 and performed a detailed investigation of the structure and function of the cerebellar vermis. We found that throughout all ten lobules of the cerebellar vermis, Purkinje cells were significantly smaller and expression of the calcium binding protein calbindin (CB) was significantly reduced. We also found that dendritic arbors of Purkinje cells were shorter and less complex. Additionally, animals exposed to a repeated dose of VPA performed significantly worse in a number of motor tasks, including beam walking and the rotarod. These results suggest that repeated embryonic exposure to VPA induces significant cerebellar dysfunction and is an effective animal model to study the cerebellar alterations in ASD. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:34 / 47
页数:14
相关论文
共 50 条
  • [11] Prenatal Exposure to Valproic Acid Across Various Indications for Use
    Smolinski, Nicole E.
    Sarayani, Amir
    Thai, Thuy N.
    Jugl, Sebastian
    Ewig, Celeste L. Y.
    Winterstein, Almut G.
    JAMA NETWORK OPEN, 2024, 7 (05) : E2412680
  • [12] Hyperplasticity in the amygdala of rat Model by prenatal exposure to valproic acid
    Lin, Hui-Ching
    Chan, Yun-Han
    Chen, Po See
    FASEB JOURNAL, 2013, 27
  • [13] Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid
    Rinaldi, Tania
    Silberberg, Gilad
    Markram, Henry
    CEREBRAL CORTEX, 2008, 18 (04) : 763 - 770
  • [14] The effects of prenatal exposure to valproic acid on the initial development of serotonergic neurons
    Oyabu, Akiko
    Narita, Masaaki
    Tashiro, Yasura
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2013, 31 (03) : 202 - 208
  • [15] Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles
    Sailer, L.
    Duclot, F.
    Wang, Z.
    Kabbaj, M.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [16] Effect of Prenatal Valproic Acid Exposure on Cortical Morphology in Female Mice
    Hara, Yuta
    Maeda, Yuko
    Kataoka, Shunsuke
    Ago, Yukio
    Takuma, Kazuhiro
    Matsuda, Toshio
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 (04) : 543 - 546
  • [17] PRENATAL VALPROIC ACID (VPA) EXPOSURE ALTERS SEIZURE SUSCEPTIBILITY IN RATS
    SOBRIAN, SK
    BURTON, LE
    ROBINSON, NL
    HODGE, KL
    FASEB JOURNAL, 1991, 5 (05): : A1237 - A1237
  • [18] Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles
    L. Sailer
    F. Duclot
    Z. Wang
    M. Kabbaj
    Scientific Reports, 9
  • [19] PRENATAL EXPOSURE TO VALPROIC ACID IN FEMALE RATS: BEHAVIOURAL IMPACT ON OFFSPRING
    Agnes, Laure Auclair
    Jankovic, Dominik
    Barret, Catherine
    Moser, Paul
    BEHAVIOURAL PHARMACOLOGY, 2013, 24 : E25 - E26